Bristol-based Neuronostics has raised £3m to accelerate BioEP, its patented digital biomarker platform for epilepsy diagnosis and prognosis.
The startup says people with suspected epilepsy wait over a year for a diagnosis, misdiagnosis rates can exceed 30% and around half are not seizure free one year after starting treatment.
An electroencephalogram (EEG) is a test that measures electrical activity in the brain. BioEP analyses background EEG activity using eight predefined computational biomarkers derived from peer-reviewed neuroscience, providing objective clinical decision support when routine EEG is inconclusive.
The new investment will enable three strategic priorities: US regulatory and reimbursement work, including an FDA submission planned for 2026; broader NHS adoption of BioEP; and development of the platform to provide brain fingerprints of treatment response in pharmaceutical trials.
The round was co-led by Empirical Ventures and The FSE Group, with participation from British Business Bank’s South West Investment Fund, Ascension Ventures, QantX, New Wave Venture Partners and Angel Investors Bristol.
The equity investment was further strengthened by a £400k Innovate UK Investor Partnerships grant.
“We have the scientific foundation and clinical evidence for BioEP. The quality of the investor syndicate reflects the strength of the commercial opportunity that builds from this,” says John Terry, cofounder and managing director of Neuronostics.
“The regulatory path is clear, the partnerships are in place and NHS adoption is building. Patients should not have to wait so long for answers. This is the reason our work matters.”
